245 related articles for article (PubMed ID: 33736976)
1. Patients' preferences for delaying metastatic castration-resistant prostate cancer: Combining health state and treatment valuation.
Rentz AM; Mansukhani SG; Liu J; Lloyd AJ; Heidenreich S; Matza LS; Dawson NA; Shore N; Freedland SJ
Urol Oncol; 2021 Jun; 39(6):367.e7-367.e17. PubMed ID: 33736976
[TBL] [Abstract][Full Text] [Related]
2. Understanding what matters to metastatic castration-resistant prostate cancer (mCRPC) patients when considering treatment options: A US patient preference survey.
George DJ; Mohamed AF; Tsai JH; Karimi M; Ning N; Jayade S; Botteman M
Cancer Med; 2023 Mar; 12(5):6040-6055. PubMed ID: 36226867
[TBL] [Abstract][Full Text] [Related]
3. Total cost of care for castration-resistant prostate cancer in a commercially insured population and a medicare supplemental insured population.
Wu B; Li SS; Song J; Pericone CD; Behl AS; Dawson NA
J Med Econ; 2020 Jan; 23(1):54-63. PubMed ID: 31589086
[No Abstract] [Full Text] [Related]
4. Health-Related Quality of Life and Health Utilities in Metastatic Castrate-Resistant Prostate Cancer: A Survey Capturing Experiences from a Diverse Sample of UK Patients.
Lloyd AJ; Kerr C; Penton J; Knerer G
Value Health; 2015 Dec; 18(8):1152-7. PubMed ID: 26686802
[TBL] [Abstract][Full Text] [Related]
5. Patient preferences for treatment of castration-resistant prostate cancer in Japan: a discrete-choice experiment.
Uemura H; Matsubara N; Kimura G; Yamaguchi A; Ledesma DA; DiBonaventura M; Mohamed AF; Basurto E; McKinnon I; Wang E; Concialdi K; Narimatsu A; Aitoku Y
BMC Urol; 2016 Nov; 16(1):63. PubMed ID: 27814714
[TBL] [Abstract][Full Text] [Related]
6. Economic Outcomes in Patients with Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate Plus Prednisone.
Ramaswamy K; Lechpammer S; Mardekian J; Huang A; Schultz NM; Sandin R; Wang L; Baser O; George DJ
Adv Ther; 2020 May; 37(5):2083-2097. PubMed ID: 32112280
[TBL] [Abstract][Full Text] [Related]
7. Earlier use of androgen receptor-axis-targeted drugs may improve overall survival in patients with non-metastatic castration-resistant prostate cancer.
Mori K; Kimura T; Ito K; Onuma H; Tanaka M; Matsuura T; Kurokawa G; Iwatani K; Inaba Y; Sakanaka K; Sasaki H; Miki J; Shimomura T; Miki K; Egawa S
Prostate; 2018 Jul; 78(10):766-772. PubMed ID: 29635810
[TBL] [Abstract][Full Text] [Related]
8. Values of alkaline phosphatase at the diagnosis of castration resistance and response to primary androgen deprivation therapy as predictors of subsequent metastasis in non-metastatic castration-resistant prostate cancer.
Mori K; Kimura T; Fukuokaya W; Iwatani K; Sakanaka K; Kurokawa G; Yanagisawa T; Sasaki H; Miki J; Shimomura T; Miki K; Hatano T; Endo K; Egawa S
Int J Clin Oncol; 2020 Mar; 25(3):479-485. PubMed ID: 31512007
[TBL] [Abstract][Full Text] [Related]
9. Patient and caregiver benefit-risk preferences for nonmetastatic castration-resistant prostate cancer treatment.
Srinivas S; Mohamed AF; Appukkuttan S; Botteman M; Ng X; Joshi N; Tsai JH; Fang J; Waldeck AR; Simmons SJ
Cancer Med; 2020 Sep; 9(18):6586-6596. PubMed ID: 32725755
[TBL] [Abstract][Full Text] [Related]
10. Disability weights for castration-resistant prostate cancer: an empirical investigation.
Borsoi L; Ciani O; Vivo R; Russo GI; Scarcia M; De Fino C; Beccaglia P; Luccarini I
Glob Reg Health Technol Assess; 2022; 9():146-154. PubMed ID: 36628321
[TBL] [Abstract][Full Text] [Related]
11. Time spent in hormone-sensitive and castration-resistant disease states in men with advanced prostate cancer, and its health economic impact: registry-based study in Sweden.
Svensson J; Lissbrant IF; Gauffin O; Hjälm-Eriksson M; Kilany S; Fagerlund K; Stattin P
Scand J Urol; 2021 Feb; 55(1):1-8. PubMed ID: 33300403
[TBL] [Abstract][Full Text] [Related]
12. Unmet needs in non-metastatic castration-resistant prostate cancer from the Japanese patient perspective: a discrete choice experiment.
Uemura H; Matsushima H; Yokomizo A; Kobayashi K; Arai G; Satoh T; Grillo V; Chen Y; Singh S; Ledesma DA
BMJ Open; 2021 Aug; 11(8):e052471. PubMed ID: 34400460
[TBL] [Abstract][Full Text] [Related]
13. Understanding how prostate cancer patients value the current treatment options for metastatic castration resistant prostate cancer.
Benidir T; Hersey K; Finelli A; Hamilton R; Joshua AM; Kulkarni G; Zlotta A; Fleshner N
Urol Oncol; 2018 May; 36(5):240.e13-240.e20. PubMed ID: 29454590
[TBL] [Abstract][Full Text] [Related]
14. Does docetaxel prolong survival of patients with non-metastatic castration-resistant prostate cancer?
Ito K; Kimura T; Onuma H; Tabata R; Shimomura T; Miki K; Tomita M; Egawa S
Prostate; 2018 May; 78(7):498-505. PubMed ID: 29473179
[TBL] [Abstract][Full Text] [Related]
15. Castration-resistant prostate cancer without metastasis at presentation may achieve cancer-specific survival in patients who underwent prior radical prostatectomy.
Kodama H; Koie T; Oikawa M; Narita T; Tanaka T; Noro D; Iwamura H; Tobisawa Y; Yoneyama T; Hashimoto Y; Ohyama C
Int Urol Nephrol; 2020 Apr; 52(4):671-679. PubMed ID: 31897875
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness analyses and cost analyses in castration-resistant prostate cancer: A systematic review.
Grochtdreis T; König HH; Dobruschkin A; von Amsberg G; Dams J
PLoS One; 2018; 13(12):e0208063. PubMed ID: 30517165
[TBL] [Abstract][Full Text] [Related]
17. Understanding Treatment Strategies and Preferences in Nonmetastatic Castration-Resistant Prostate Cancer From the Japanese Physician Perspective.
Suzuki K; Grillo V; Chen Y; Singh S; Ledesma DA
JCO Glob Oncol; 2021 Feb; 7():302-310. PubMed ID: 33617305
[TBL] [Abstract][Full Text] [Related]
18. Physician preferences for non-metastatic castration-resistant prostate cancer treatment.
Srinivas S; Mohamed AF; Appukkuttan S; Botteman M; Ng X; Joshi N; Horodniceanu E; Waldeck AR; Simmons SJ
BMC Urol; 2020 Jun; 20(1):73. PubMed ID: 32571276
[TBL] [Abstract][Full Text] [Related]
19. Predictors of survival, healthcare resource utilization, and healthcare costs in veterans with non-metastatic castration-resistant prostate cancer.
Freedland SJ; Pilon D; Bhak RH; Lefebvre P; Li S; Young-Xu Y
Urol Oncol; 2020 Dec; 38(12):930.e13-930.e21. PubMed ID: 32739230
[TBL] [Abstract][Full Text] [Related]
20. Patients' Preferences for the Treatment of Metastatic Castrate-resistant Prostate Cancer: A Discrete Choice Experiment.
Eliasson L; de Freitas HM; Dearden L; Calimlim B; Lloyd AJ
Clin Ther; 2017 Apr; 39(4):723-737. PubMed ID: 28366592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]